Nature Communications

RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11b+ Bregs thereby overcoming melanoma PD1-resistance

2026-01-12

Full text

DOI https://doi.org/10.1038/s41467-025-67315-1